{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-24-000021","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.769040+00:00","generated_at":"2026-06-04T05:21:47.158498+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elicio Therapeutics reports FY2023 net loss $35.2M; cash boosted by $6M private placement","bullets":["Net loss of $35.2M for FY2023 vs $28.2M in FY2022; diluted EPS -$6.96 vs -$89.27 (reverse-merger impact).","Cash and cash equivalents $12.9M at Dec 31, 2023; $6.0M private placement closed in March 2024.","ELI-002 2P Phase 1a data in Nature Medicine: 84% T cell response, 24% biomarker clearance, median RFS 16.33 months.","Phase 2 randomized trial of ELI-002 7P in PDAC started; enrollment expected to complete Q4 2024.","Initial clinical data from ELI-002 7P Phase 1 trial anticipated in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-24-000021","json":"https://secwatch.observer/filing/0001601485-24-000021.json","markdown":"https://secwatch.observer/filing/0001601485-24-000021.md","text":"https://secwatch.observer/filing/0001601485-24-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000021/0001601485-24-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000021/angn-20240329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:21:47.158498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9fb06bb6ef6abd899de8b27c7b845583d0df2498","claim":"Elicio Therapeutics, Inc. reported the year ending December 31, 2023 results: net income Net loss for 2023 was $35.2 million, EPS Net loss per share for 2023 was $6.96.","evidence_excerpt":"Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2023 and provided corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000021/0001601485-24-000021-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ending December 31, 2023"},{"label":"Net income","value":"Net loss for 2023 was $35.2 million"},{"label":"EPS","value":"Net loss per share for 2023 was $6.96"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}